Shots:
- Bio-Thera to receive $165M upfront, regulatory, and commercial milestones and is eligible to receive royalties on sales of the product. BeiGene to get the right to develop, manufacture, and commercialize BAT1706 in China, including Hong Kong, Macau, and Taiwan while Bio-Thera will retain rights for the therapy outside the licensed territory
- The NMPA has recently accepted the BLA for BAT1706. The collaboration allows Bio-Thera to leverage BeiGene’s expertise to accelerate the development and commercialization of BAT1706 as a single agent regimen or as a component of combinational therapies
- BAT1706 is a mAb, a biosimilar referencing Avastin which is a treatment option for solid tumor indications in China such as colorectal, lung, and liver cancers. Additionally, Bio-Thera plans to file for the approval of BAT1706 in the US and EU in the Q4’20
Click here to read full press release/ article | Ref: BeiGene Image: JHL Biotech
